Researchers have released the first results from a phase Ib international study testing the combination of regorafenib, a targeted therapy, with standard chemotherapy for patients newly diagnosed with multi-metastatic Ewing sarcoma. This rare and aggressive cancer mainly affects children and young adults. The study aimed to find the safest and most effective dose of regorafenib when used alongside existing treatments. Early findings suggest the combination is tolerable and could offer new hope for patients facing this challenging diagnosis, paving the way for further clinical trials and improved therapies in the future.